Rx Product News

Published Online: Wednesday, June 13, 2012
Follow Pharmacy_Times:

FluMist Quadrivalent

Marketed by: MedImmune (Gaithersburg, MD)

Indication: MedImmune announced the FDA approval of FluMist Quadrivalent (Influenza Vaccine Live, Intranasal) for the prevention of influenza infection. The first quadrivalent vaccine approved by the FDA, FluMist Quadrivalent contains 4 strains of influenza, with 2 strains each of types A and B. It is approved for patients aged 2 to 49 years. Each intranasal sprayer contains 0.2 mL; 0.1 mL is administered into each nostril. FluMist Quadrivalent will be available starting with the 2013-2014 flu season.

Dosage Form: Intranasal spray: each 0.2- mL dose is supplied in a single-dose, prefilled intranasal sprayer.

For More Information: www.flumistquadrivalent.com


VitaMedMD RediChew RX

Marketed by: TherapeuticsMD, Inc (Boca Raton, FL)

Indication: TherapeuticsMD, Inc announced the launch of vitaMedMD RediChew Rx, a prescription prenatal vitamin for women planning a pregnancy and pregnant women who have difficulty swallowing tablets or capsules. Each vanilla-flavored, chewable tablet is taken once daily and contains 1 mg of a proprietary form of folate, 400 IU of vitamin D3 , 1.7 mg of vitamin B 2 , 2 mg of vitamin B 6 , and 8 mcg of vitamin B 12 . VitaMedMD RediChew Rx is available by prescription through chain, independent, and mail order pharmacies.

Dosage Form: Chewable tablets: 30-count package

For More Information: www.vitamedmdrx.com


Marketed by: Novo Nordisk (Princeton, NJ)

Indication: Novo Nordisk announced the FDA approval of an expansion of Levemir’s (insulin detemir [rDNA origin] injection) indication to include use in children aged 2 to 5 years with type 1 diabetes. It is the first and only basal insulin analog for use in this population. Levemir is administered either twice daily in divided doses or once daily with the evening meal or at bedtime. It is not recommended for treating diabetic ketoacidosis.

Dosage Form: Solution for injection: 100 units/mL in a 3-mL FlexPen or 10-mL vial.

For More Information: www.levemir.com

Fabior Foam, 0.1%

Marketed by: Stiefel, a GSK Company (Research Triangle Park, NC)

Indication: The FDA approved Fabior (tazarotene) Foam, 0.1%, a retinoid indicated for the topical treatment of acne vulgaris in patients 12 years or older. Patients should apply a thin layer of Fabior Foam once daily in the evening to the entire affected area of the face and/or upper trunk, avoiding the eyes, lips, and mucous membranes. After application, patients should wash their hands. Because it contains tazarotene, a teratogenic substance, Fabior Foam is contraindicated during pregnancy.

Dosage Form: Foam for topical use: 0.1%.

For More Information: www.stiefel.com

Related Articles
Sanofi has announced the FDA approval of its insulin glargine injection (Toujeo), a once-daily long-acting basal insulin, for the improvement of glycemic control in adults with type 1 and type 2 diabetes.
Novo Nordisk has positive results from a completed phase 2 trial on the oral formulation of its investigational, long-acting human glucagon-like peptide-1 analogue.
Many patients with non-alcoholic fatty liver disease also have low vitamin D levels.
A recent report from the Centers for Disease Control and Prevention has estimated that this season’s flu vaccine is reducing the risk of medical visits associated with influenza by 23%.
Latest Issues
  • photo
    Pharmacy Times
    Health-System Edition
    Directions in Pharmacy
    OTC Guide
    Generic Supplements
  • photo
    Pharmacy Careers
    Specialty Pharmacy Times